Genworth Financial (NYSE:GNW) Stock Passes Above 50-Day Moving Average of $3.46

Share on StockTwits

Genworth Financial Inc (NYSE:GNW)’s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $3.46 and traded as high as $3.85. Genworth Financial shares last traded at $3.79, with a volume of 37,330 shares.

Several equities research analysts have recently issued reports on the stock. BTIG Research restated a “hold” rating on shares of Genworth Financial in a report on Tuesday, July 2nd. Zacks Investment Research lowered shares of GasLog Partners LP Unit from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 2nd. Finally, ValuEngine upgraded shares of XCel Brands from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th.

The company has a fifty day moving average price of $3.46. The stock has a market cap of $1.93 billion, a PE ratio of 10.42 and a beta of 1.78. The company has a current ratio of 0.27, a quick ratio of 0.27 and a debt-to-equity ratio of 0.27.

Genworth Financial (NYSE:GNW) last released its earnings results on Tuesday, April 30th. The financial services provider reported $0.24 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by ($0.02). The firm had revenue of $2.20 billion during the quarter, compared to the consensus estimate of $2.13 billion. Genworth Financial had a return on equity of 1.20% and a net margin of 2.12%. Genworth Financial’s revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.25 EPS. Research analysts expect that Genworth Financial Inc will post 0.97 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. NEXT Financial Group Inc grew its position in shares of Genworth Financial by 260.2% in the 2nd quarter. NEXT Financial Group Inc now owns 73,837 shares of the financial services provider’s stock worth $274,000 after buying an additional 53,337 shares during the last quarter. CWM Advisors LLC grew its position in shares of Genworth Financial by 15.5% in the 2nd quarter. CWM Advisors LLC now owns 46,059 shares of the financial services provider’s stock worth $171,000 after buying an additional 6,191 shares during the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of Genworth Financial by 2.1% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 202,178 shares of the financial services provider’s stock worth $750,000 after buying an additional 4,166 shares during the last quarter. New Jersey Better Educational Savings Trust purchased a new position in shares of Genworth Financial in the 2nd quarter worth approximately $148,000. Finally, Retirement Systems of Alabama grew its position in shares of Genworth Financial by 0.3% in the 2nd quarter. Retirement Systems of Alabama now owns 923,559 shares of the financial services provider’s stock worth $3,426,000 after buying an additional 2,795 shares during the last quarter. 65.85% of the stock is currently owned by institutional investors.

Genworth Financial Company Profile (NYSE:GNW)

Genworth Financial, Inc provides insurance and homeownership solutions in the United States and internationally. It operates through five segments: U.S. Mortgage Insurance, Canada Mortgage Insurance, Australia Mortgage Insurance, U.S. Life Insurance, and Runoff. The U.S. Mortgage Insurance segment offers mortgage insurance products primarily insuring prime-based, individually underwritten residential mortgage loans.

Further Reading: Death Cross

Receive News & Ratings for Genworth Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genworth Financial and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nabriva Therapeutics  Shares Up 5.6%
Nabriva Therapeutics Shares Up 5.6%
Graham Co.  Given $27.00 Consensus Target Price by Analysts
Graham Co. Given $27.00 Consensus Target Price by Analysts
Analysts Set $5.75 Target Price for Luna Innovations Incorporated
Analysts Set $5.75 Target Price for Luna Innovations Incorporated
Analysts Set Aridis Pharmaceuticals Inc  PT at $32.00
Analysts Set Aridis Pharmaceuticals Inc PT at $32.00
Lineage Cell Therapeutics  Stock Price Up 12%
Lineage Cell Therapeutics Stock Price Up 12%
BioMarin Pharmaceutical  Trading 6.6% Higher
BioMarin Pharmaceutical Trading 6.6% Higher


 
© 2006-2019 Zolmax.